Drug Profile
Research programme: EVade ribonucleases - Quintessence Biosciences
Alternative Names: PEG-RNases - Quintessence; QBI-206Latest Information Update: 27 Dec 2022
Price :
$50
*
At a glance
- Originator Quintessence Biosciences
- Class Ribonucleases
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Discontinued Cancer; Immunological disorders; Inflammation
Most Recent Events
- 27 Dec 2022 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 27 Dec 2022 Discontinued for Immunological disorders in USA (unspecified route)
- 27 Dec 2022 Discontinued for Inflammation in USA (unspecified route)